BioCentury
ARTICLE | Company News

Pfizer, Cystic Fibrosis Foundation deal

December 3, 2012 8:00 AM UTC

Pfizer partnered with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the drug development affiliate of the not-for-profit foundation, to discover and develop therapies to treat cystic fibrosis in patients with the delta F508 mutation in the CF transmembrane conductance regulator ( CFTR) protein. Under the deal, CFFT will invest up to $58 million to develop undisclosed preclinical candidates, with the goal of advancing one or more into the clinic by the end of the six-year program. The parties could not be reached for details. ...